DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: BYR-34380 |   Chemical

Historical data: 2017 - 2023

Forecast period: 2025 - 2031

Quantitative units: Revenue in USD million and CAGR from 2025 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Drugs for Respiratory Syncytial Virus (RSV) Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET

7.1 GLOBAL DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)

8.1 GLOBAL DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

8.2 GLOBAL DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

9.1 GLOBAL DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

9.2 GLOBAL DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

10.1 GLOBAL DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)

10.2 GLOBAL DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)

11.1 NORTH AMERICA DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

11.2 NORTH AMERICA DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

11.3 NORTH AMERICA DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

11.4 NORTH AMERICA DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

11.5 NORTH AMERICA DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

11.6 NORTH AMERICA DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

12.1 EUROPE DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

12.2 EUROPE DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

12.3 EUROPE DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

12.4 EUROPE DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

12.5 EUROPE DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

12.6 EUROPE DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

13.1 ASIA PACIFIC DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

13.2 ASIA PACIFIC DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

13.3 ASIA PACIFIC DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

13.4 ASIA PACIFIC DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

13.5 ASIA PACIFIC DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

13.6 ASIA PACIFIC DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

14.1 LATIN AMERICA DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>

14.2 LATIN AMERICA DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

14.3 LATIN AMERICA DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

14.4 LATIN AMERICA DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

14.5 LATIN AMERICA DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

14.6 LATIN AMERICA DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA DRUGS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>

16.1 Ablynx

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 ADMA Biologics

16.3 AlphaVax

16.4 AmVac

16.5 Aridis Pharmaceuticals

16.6 Artificial Cell Technologies

16.7 Astellas Pharma

16.8 AstraZeneca

16.9 Bavarian Nordic

16.10 Agilvax

16.11 Biota Pharmaceuticals

16.12 Celltrion

16.13 Codagenix

16.14 Crucell

16.15 CureVac

16.16 Emergent

16.17 Roche

16.18 GenVec

16.19 Gilead Sciences

16.20 GlaxoSmithKline

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

Market by Type :

Ribavirin
Bronchodilator

Market by Application :

Infants (Under 6 Month Old)
Babies & Children
Adults

Companies

Ablynx
ADMA Biologics
AlphaVax
AmVac
Aridis Pharmaceuticals
Artificial Cell Technologies
Astellas Pharma
AstraZeneca
Bavarian Nordic
Agilvax
Biota Pharmaceuticals
Celltrion
Codagenix
Crucell
CureVac
Emergent
Roche
GenVec
Gilead Sciences
GlaxoSmithKline

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE
  • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY
  • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH
  • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING
  • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.